The DOI matches its Crossref record.
Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome
Abstract
The Li-Fraumeni cancer predisposition syndrome is associated with germline TP53 mutations in the majority of families. We have investigated cancer incidence in 34 Li-Fraumeni families, according to their constitutional TP53 mutation status. Families with germline missense mutations in the core DNA binding domain showed a more highly penetrant cancer phenotype than families with other TP53 mutations or no mutation. Cancer phenotype in families carrying such mutations was characterized by a higher cancer incidence and earlier ages at diagnosis, especially of breast cancer and brain tumours, compared with families carrying protein truncating or other inactivating mutations (P=0.03 for all cancers, P=0.006 for breast cancers, P=0.05 for brain tumours). Proband cancers showed significantly younger ages at diagnosis in those with missense mutations in the DNA binding domain than in those with protein inactivating mutations (P=0.031). In individuals with the former type of mutation, there was a significantly lower proportion of tumours which showed loss of the wild-type TP53 allele (P=0.004). These results are consistent with observations in experimental systems which demonstrate that certain mutations exhibit gain of function and/or dominant-negative properties. Our results support an enhanced oncogenic potential for such mutations in human populations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In Li-Fraumeni syndrome (LFS), individuals with TP53 missense mutations show a higher cancer incidence and an earlier age of tumor onset than individuals with truncating or splicing mutations (Birch, et al., 1998).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Birch, et al., 1998
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 101–200 of 200
The inherited susceptibility to cancer
Guilford, P. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000721 · Cited by 24
Patel, M. M., & Adrada, B. E. (2024) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2023.12.014 · Cited by 21
Upton, B., Chu, Q. D., & Li, B. D. �. (2008) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2008.08.006 · Cited by 21
Bendig, I., Mohr, N., Krämer, F., & Weber, B. H. F. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.02.017 · Cited by 21
BRCA and Breast Cancer-Related High-Penetrance Genes
Han, S., & Kim, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_25 · Cited by 22
D4S234E, a novel p53-responsive gene, induces apoptosis in response to DNA damage
Kudoh, T., Kimura, J., Lu, Z., Miki, Y., & Yoshida, K. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.06.025 · Cited by 20
The p53 Tumor Suppressor Pathway and Cancer
Zambetti, G. P. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5 · Cited by 20
Absence of Germline CHK2 Mutations in Familial Gastric Cancer
Kimura, K., Shinmura, K., Yoshimura, K., Shimizu, K., Katai, H., Beppu, Y., Moriya, H., & Yokota, J. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb01028.x · Cited by 19
Shen, L. H., Zhang, S., Wang, K., & Wang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.740227 · Cited by 21
Genotype Phenotype Correlation in Li-Fraumeni Syndrome Kindreds and its Implications for Management
Moule, R. N., Jhavar, S. G., & Eeles, R. A. (2006) · Familial Cancer · doi:10.1007/s10689-005-4522-8 · Cited by 18
Trková, M., Foretová, L., Kodet, R., Hedvičáková, P., & Sedláček, Z. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00031-1 · Cited by 17
Rossbach, H., Baschinsky, D. Y., Wynn, T., Obzut, D. A., Sutcliffe, M. J., & Tebbi, C. K. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21219 · Cited by 16
Molecular genetics complexity impeding research progress in breast and ovarian cancers
Gupta, I., Burney, I. A., Al-Moundhri, M. S., & Tamimi, Y. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1275 · Cited by 15
Li–Fraumeni syndrome in a Malaysian kindred
Ariffin, H., Martel‐Planche, G., Daud, S. S., Ibrahim, K., & Hainaut, P. L. (2008) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2008.06.004 · Cited by 15
Late-Onset Common Cancers in a Kindred with an Arg213Gln TP53 Germline Mutation
Ruijs, M., Verhoef, S., Wigbout, G., Pruntel, R., Floore, A. N., de Jong, D., Veer, L. V. ‘., & Menko, F. H. (2006) · Familial Cancer · doi:10.1007/s10689-005-4789-9 · Cited by 15
Akeno, N., Reece, A. L., Callahan, M. K., Miller, A. L., Kim, R. G., He, D., Lane, A., Moulton, J. S., & Wikenheiser‐Brokamp, K. A. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0353 · Cited by 15
Foulkes, W. D., Rosenblatt, J. M., & Chappuis, P. O. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1014791115760 · Cited by 15
Novel oncogene amplifications in tumors from a family with Li–Fraumeni syndrome
Rieber, J., Remke, M., Hartmann, C. J., Korshunov, A., Burkhardt, B., Sturm, D., Mechtersheimer, G., Wittmann, A., Greil, J., Blattmann, C., et al. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20665 · Cited by 14
Germline p53 Mutation in a Patient with Multiple Primary Cancers
Kimura, K. (2001) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hye070 · Cited by 14
A new paradigm of genetic testing for hereditary breast/ovarian cancers
Kwong, A., Chen, J. W., & Shin, V. Y. (2016) · Hong Kong Medical Journal · doi:10.12809/hkmj154634 · Cited by 17
Capponcelli, S., Pedrini, E., Cerone, M. A., Corti, V., Fontanesi, S., Alessio, M., Bachi, A., Soddu, S., Ribatti, D., Picci, P., et al. (2005) · Human Mutation · doi:10.1002/humu.20192 · Cited by 15
Potential of Advexin ® : A p53 Gene-Replacement Therapy in Li–Fraumeni Syndrome
Nemunaitis, J., & Nemunaitis, J. J. (2008) · Future Oncology · doi:10.2217/14796694.4.6.759 · Cited by 14
Bertagnolli, M. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.096 · Cited by 14
p53 transdominance but no gain of function in mouse brain tumor model.
Hegi, M. E., Klein, M. A., Rüedi, D., Chêne, P., Hamou, M., & Aguzzi, A. (2000) · PubMed · Cited by 13
The Anti-Apoptosis Survivin Gene and its Role in Human Cancer: An Overview
Escuín, D., & Rosell, R. (1999) · Clinical Lung Cancer · doi:10.3816/clc.1999.n.011 · Cited by 13
Wang, S., Chen, L., Zhao, Q., Huan, R., Wang, M., Gong, W., Zhou, J., Wu, D., & Zhang, Z. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2103-3 · Cited by 14
Dominant-negative p53-overexpression in skeletal muscle induces cell death and fiber atrophy in rats
Langer, H. T., Mossakowski, A. A., Sule, R. O., Gomes, A. V., & Baar, K. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05160-6 · Cited by 13
Klein, M. A., Rüedi, D., Nozaki, M., Dell, E. W., Diserens, A., Seelentag, W. K. F., Janzer, R. C., Aguzzi, A., & Hegi, M. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203941 · Cited by 11
Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10
Germline variant affecting p53β isoforms predisposes to familial cancer
Schubert, S. A., Ruano, D., Joruiz, S. M., Stroosma, J., Glavak, N., Montali, A., Pinto, L., Rodríguez‐Girondo, M., Barge‐Schaapveld, D. Q. C. M., Nielsen, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52551-8 · Cited by 10
Identification of a novel p53 in‐frame deletion in a Li–Fraumeni‐like family
Schiffman, J. D., Chun, N. M., Fisher, P. G., Dahl, G. V. H., Ford, J. M., & Eggerding, F. A. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21247 · Cited by 9
Umbilical cord blood transplantation
Will, A. (1999) · Archives of Disease in Childhood · doi:10.1136/adc.80.1.3 · Cited by 9
Bioinformatic analysis reveals the key pathways and genes in early-onset breast cancer
Cui, C., Li, L., & Zhen, J. (2018) · Medical Oncology · doi:10.1007/s12032-018-1130-7 · Cited by 8
Piao, J., Sakurai, N., Iwamoto, S., Nishioka, J., Nakatani, K., Komada, Y., Mizutani, S., & Takagi, M. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21912 · Cited by 7
Figueiredo (2010) · International Journal of Oncology · doi:10.3892/ijo_00000578 · Cited by 8
Genes implicated in hereditary breast cancer syndromes.
Tonin, P. (2000) · Seminars in surgical oncology · doi:10.1002/(sici)1098-2388(200006)18:4 · Cited by 35
The TP53 Tumor Suppressor Gene: Structure and Function☆
Becker, K. A., & Jerry, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.98757-9 · Cited by 8
Cancer genetics in primary care
Culler, D., Grimes, S. J., Acheson, L. S., & Wiesner, G. L. (2004) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2004.05.001 · Cited by 8
Epidemiology and Etiology of Cancer in Adolescents and Young Adults
Birch, J. M., & Bleyer, A. (2007) · Springer eBooks · doi:10.1007/978-3-540-68152-6_3 · Cited by 7
Self-citationCancer and Genomic Instability
Wei, W., Cheng, Y., & Wang, B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803309-8.00027-6 · Cited by 7
BRCA/Fanconi anemia pathway genes in hereditary predisposition to breast cancer
Sólyom, S. (2011) · Cited by 7
Portwine, C., & Malkin, D. M. (2001) · Encyclopedia of Life Sciences · doi:10.1038/npg.els.0001893 · Cited by 7
Marruecos, L., Manils, J., Moreta-Moraleda, C., Gómez, D., Filgaira, I., Serafín, A., Cañas, X., Espinosa, L., & Soler, C. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03638-3 · Cited by 6
Stecher, C. W., Grønbæk, K., & Hasle, H. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.21074 · Cited by 6
Arango-Ibañez, J. P., Parra‐Lara, L. G., Zambrano, A. R., & Rodríguez‐Rojas, L. X. (2024) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-023-00272-2 · Cited by 5
Genetic counseling and testing for Li-Fraumeni syndrome: the medical and psychosocial implications
Vogel, K. J., & Shannon, K. (2009) · Community Oncology · doi:10.1016/s1548-5315(11)70360-6 · Cited by 5
Murray, K. S., Spaliviero, M., Tonorezos, E. S., Lacouture, M. E., Tap, W. D., Oeffinger, K. C., Vargas, H. A., & Eastham, J. A. (2018) · Urology · doi:10.1016/j.urology.2018.06.008 · Cited by 5
Colorectal Cancer: Epidemiology, Etiology, and Molecular Basis
Baxter, N. N., & Guillem, J. G. (2007) · Springer eBooks · doi:10.1007/978-0-387-36374-5_23 · Cited by 5
Lefrou, L., Godart, B., Muret, A. D., Scotto, B., & Dorval, E. D. (2006) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(06)73212-2 · Cited by 5
Non-random genomic instability in cancer: A fact, not an illusion
Mai, S., & Imreh, S. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.11.002 · Cited by 5
Cancer of the Breast and Female Reproductive Tract
Gordon, O. K. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00093-8 · Cited by 5
Patterns of Incidence of Cancer in Teenagers and Young Adults: Implications for Aetiology
Birch, J. M. (2005) · doi:10.1002/9780470994733.ch2 · Cited by 5
Self-citationDistinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers
Boruah, N., Hoyos, D., Moses, R., Hausler, R. M., Desai, H., Le, A. D., Good, M., Kelly, G., Raghavakaimal, A., Tayeb, M. N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73163-4 · Cited by 4
Polidorio, N., Sandoval, R. L., Bioni, P., Pisani, J. P., & Achatz, M. I. (2025) · Scientific Reports · doi:10.1038/s41598-025-89068-z · Cited by 3
Colorectal Cancer: Epidemiology, Etiology, and Molecular Basis
Moore, H. G., Baxter, N. N., & Guillem, J. G. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1584-9_38 · Cited by 3
The Oncogenic Activity of p53 Mutants
Sigal, A., & Rotter, V. (2007) · Springer eBooks · doi:10.1007/0-387-30127-5_9 · Cited by 3
Cancer and genomic instability
Kovalchuk, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85679-9.00026-x · Cited by 3
Genetics and the Multidisciplinary Breast Center
Peters, J. A., & Rubinstein, W. S. (2000) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30159-5 · Cited by 3
Villani, A., Frébourg, T., & Malkin, D. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-74448-9_1 · Cited by 2
TP53 Germline Mutations: Genetics of Li–Fraumeni Syndrome
Bakry, D., & Malkin, D. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_10 · Cited by 2
Chatterjee, M., Chinder, P. S., Mannan, A. U., Sheela, M. L., Mukherjee, U., Choudhury, S., Lo, C., Singh, S., Singh, J., Hazarika, D., et al. (2016) · International Journal of Human Genetics · doi:10.1080/09723757.2016.11886284 · Cited by 2
Risk Assessment & Genetic Testing
Chappuis, P. O., & Foulkes, W. D. (2002) · Springer eBooks · doi:10.1007/978-1-4757-3587-1_2 · Cited by 2
The Li–Fraumeni syndrome and the role of TP53 mutations in predisposition to cancer
Birch, J. M. (2004) · CRC Press eBooks · doi:10.1201/b13271-15 · Cited by 2
Self-citationGerber, V. K. Q., Paraizo, M. M., Ibañez, H. C., da Rocha, J. C. C., Pinto, E. M., de Andrade, D. P., Ibañez, M. V. C., Komechen, H., Figueiredo, M. M. O., Custódio, G., et al. (2022) · Cancers · doi:10.3390/cancers14123014 · Cited by 2
TP53 Tumor Suppressor Gene: Structure and Function
Jerry, D. J., & Ozbun, M. A. (2002) · Elsevier eBooks · doi:10.1016/b0-12-227555-1/00180-5 · Cited by 2
A prospective biological study in relation to a family with Li-Fraumeni syndrome
Sáez, O. A., Calvo, B., Fernández‐Teijeiro, A., Pérez, P., & Navajas, A. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0815-1 · Cited by 1
Colorectal Neoplasia Rates in Li-Fraumeni Syndrome
Spiegel, S. R., Orr, C., Edgar, N. U., Cahill, S. R., Le, A. N., Good, M., Lyman, J., Feola, S., Mehrhoff, C. J., Naumer, A., et al. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003976 · Cited by 1
Chrisanthar, R. (2009) · Cited by 1
Predisposing genes in hereditary breast and ovarian cancer
Huusko, P. (1999) · Cited by 1
Li–Fraumeni syndrome: a role for surgical pathologists?
Dickson, B. C. (2012) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2012.01.003 · Cited by 1
UV Response of Mammalian p53 Tumor Supressor Gene
Mälkönen, T. (1999) · Työväentutkimus Vuosikirja · Cited by 1
Inherited Predispositions to Cancer
Evans, D. G. (2005) · The Cancer Handbook · doi:10.1002/0470025077.chap04 · Cited by 1
Self-citationThe p53 Transcription Factor as Therapeutic Target in Cancer
Asker, C., Bykov, V. J. N., Méndez‐Vidal, C., Selivanova, G., Wilhelm, M., & Wiman, K. G. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18932-6_7 · Cited by 1
Genetic and cytogenetic studies in inherited cancer: Li-Fraumeni syndrome
Varley, J. M., Boyle, J. M., James, L. M., McGown, G., Thorncroft, M. R., Greaves, M. J., Kelsey, A. M., Evans, D. G., & Birch, J. M. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8484-6_18
Self-citationInherited Cancer-Predisposing Syndomes
Hodgson, S. V., Foulkes, W. D., Eng, C., & Maher, E. R. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2375-0_11
Li-Fraumeni syndrome, clinical and molecular genetics
Ruijs, M. (2010) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
The Role of Angiogenesis in Breast Cancer Progression
McLeskey, S. W., & Dickson, R. B. (2001) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-0213-4_3
Identificaçao de marcador embrionário em tumor de córtex adrenal de crianças
Rodrigues, G. A. (2004) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Efficient Classifier for TP53 Mutants using Feature Relevance Analysis
Poonkuzhali, S., Ramani, R. G., & Kumar, R. K. (2012)
Li–Fraumeni syndrome and the p53 tumor suppressor pathway
Irwin, M. S., & Malkin, D. M. (2006) · CRC Press eBooks · doi:10.1201/b13439-62
Loss of BRCA1 in Normal Human Mammary Epithelial Cells Induces a Novel Mechanism of Senescence
Noor, S. (2011) · TSpace (University of Toronto)
Investigation of PIN1 as a Genetic Modifier in Li-Fraumeni Syndrome
Villani, A. (2015) · TSpace (University of Toronto)
de Gouvêa, A. C. R. C., & Garber, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_8
Patched Domain-containing 4 (PTCH53) Identified in Li-Fraumeni Syndrome Patient-derived Cells
Pan, A. (2018) · TSpace (University of Toronto)
Macedo, G. D. S. (2012) · Americanae (AECID Library)
The Role of p53 in Colorectal Cancer
Masciari, S., & Syngal, S. (2009) · Springer eBooks · doi:10.1007/978-0-387-09568-4_14
Paediatric Brain Tumours: Rare Variants
Lim, J. X., Qiu, L., Low, S. Y. Y., & Seow, W. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-80522-7_24
Rabinowicz, R., & Malkin, D. M. (2021) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0029375
Chen, J.-H., Huang, P., Shi, Y., Mo, S., Hsu, C.-Y., Fang, S., Zhong, C., Zhang, L., Zuo, L., Lu, J., et al. (2025) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2025.100406
Multihit Somatic Mosaicism of TP53 Pathogenic Variants in a Patient Mimicking Li-Fraumeni Syndrome
Yokoyama, K., Yokoyama, N., Shinozaki‐Ushiku, A., Ito, M., Takamori, H., Takahashi, S., Shimizu, E., Imoto, S., Todo, T., & Nannya, Y. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00392
Genetic Counseling for TP53 Germline Mutations
Achatz, M. I., & Ashton‐Prolla, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_18
A Study of the Aetiology and Epidemiology of Cancers in Teenagers and Young Adults
Arora, R. S. (2011) · Research Explorer (The University of Manchester)
Nehrulia, D., Shapochka, D., Dekar, D., Fesenko, A. Y., Shtefan, N., Moskalenko, A., Tukalo, M. A., & Tkachuk, Z. Y. (2026) · Cytology and Genetics · doi:10.3103/s009545272601007x
Kim, K.-Y. (2004) · Journal of the Korean Chemical Society · doi:10.5012/jkcs.2004.48.1.033
Metadata
- Authors
- Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M.
- Affiliations
- Royal Manchester Children's Hospital (GB)
- Cancer Research UK Manchester Institute (GB)
- Venue
- Oncogene
- Published
- 1998-09-03
- Volume
- 17
- Issue
- 9
- Pages
- 1061-1068
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2051611229
- Cited by
- 200
- References
- 0
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 7 · 2020: 1 · 2019: 2 · 2018: 5 · 2017: 5 · 2016: 7 · 2015: 3 · 2014: 8 · 2013: 8 · 2012: 15
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- Li-Fraumeni syndrome, TP53 mutation, missense mutations, DNA-binding domain, cancer susceptibility, cancer incidence, age at diagnosis, breast cancer, brain tumors, gain-of-function, dominant negative mutation
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, DNA Mutational Analysis, Family, Family Health, Female, Genotype, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Pedigree, Phenotype, Cohort Studies, Chi-Square Distribution, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Germ-Line Mutation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review